Zafgen prices upsized IPO at $16, the high end of the range


Shutterstock photo

Zafgen, a biotech developing a treatment for severe obesity and hunger-related disorders, raised $96 million by offering 6 million shares (upsized from 5 million) at $16, the high end of the range of $14 to $16. Zafgen plans to list on the NASDAQ under the symbol ZFGN. Zafgen initially filed confidentially on 1/31/2014. Leerink Partners and Cowen & Company acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by